About 60 percent of patients who have a stem cell transplant experience a complication called graft-versus-host disease (GVHD), in which cells from the donor attack tissues of the recipient. Symptoms of GVHD include rash, digestive problems, weight loss, and liver dysfunction.
GVHD is usually treated with corticosteroid drugs, but in some patients the condition persists despite this therapy. The purpose of this study is to evaluate the effectiveness of a novel treatment called Prochymal in children with GVHD of the skin, liver, and/or intestines that persists despite steroids.
Prochymal contains adult human mesenchymal stem cells, which may help repair tissues damaged by GVHD by suppressing the immune response that triggers this condition. Patients will receive Prochymal in addition to the standard care for GVHD.